Bio-Techne’s first quarter was marked by a negative market reaction, with revenue coming in below Wall Street expectations. Management attributed the shortfall primarily to continued softness in emerging biotech demand and the impact of order timing from two cell therapy customers with FDA Fast Track Designation. CEO Kim Kelderman acknowledged that, despite stable performance from large pharmaceutical customers and improving trends in U.S. academia, the emerging biotech segment “was indeed our surprise,” as early-stage funding remained weak and order activity lagged expectations.
Is now the time to buy TECH? Find out in our full research report (it’s free for active Edge members).
Bio-Techne (TECH) Q1 CY2026 Highlights:
- Revenue: $311.4 million vs analyst estimates of $316.4 million (1.5% year-on-year decline, 1.6% miss)
- Adjusted EPS: $0.53 vs analyst estimates of $0.53 (in line)
- Adjusted EBITDA: $116.7 million vs analyst estimates of $115.4 million (37.5% margin, 1.1% beat)
- Operating Margin: 24.2%, up from 12.2% in the same quarter last year
- Organic Revenue fell 2% year on year (miss)
- Market Capitalization: $7.42 billion
While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Bio-Techne’s Q1 Earnings Call
-
Matthew Larew (William Blair) asked about intra-quarter biotech trends; CEO Kim Kelderman explained that, despite stronger funding, early-stage biotech funding was still down and customer order activity remained muted.
-
Puneet Souda (Leerink Partners) questioned the potential for mid-single-digit growth next year; CFO James Hippel said he would be disappointed if that was not achieved, citing normalization trends and core business resilience.
-
Patrick Donnelly (Citi) inquired about China’s outlook; Kelderman said the team expects continued momentum in China, citing direct market presence and strong customer ties as drivers.
-
Justin Bowers (Deutsche Bank) sought clarity on early signs of a biotech recovery; Hippel pointed to rising interest and funnel growth within proteomic analysis and spatial biology as leading indicators, but cautioned that order conversion is not yet evident.
-
Kyle Boucher (TD Cowen) asked about the sustainability of high growth in GMP reagent and spatial biology; Kelderman responded that deeper customer spend, expanding clinical programs, and market mix shifts are supporting these trends, though easy comps also help.
Catalysts in Upcoming Quarters
In the next few quarters, the StockStory team will watch (1) whether emerging biotech order activity finally reflects the recent rebound in funding, (2) further traction and backlog expansion in the COMET and Ella platforms, and (3) continued stabilization in academic and international markets, particularly China. The normalization of order timing in cell therapy and OEM channels will also be key signposts for sustained revenue growth.
Bio-Techne currently trades at $47.41, down from $56.68 just before the earnings. In the wake of this quarter, is it a buy or sell? Find out in our full research report (it’s free).
High-Quality Stocks for All Market Conditions
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren't just high-quality businesses. Something is happening with them right now. Elite fundamentals meeting near-term momentum - both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week's Strong Momentum stocks - FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.
